Why the study?
Insulin-treated type 2 diabetes mellitus is associated with a higher cardiovascular risk profile, but its impact on MACE following PCI remains unclear.
Does insulin therapy compared to non-insulin therapy increase MACE in T2DM patients following PCI?
Population
465 T2DM patients undergoing PCI and completing 1-year follow-up
Comparison
ITDM vs Non-ITDM
Design
Single-center prospective cohort study
Follow-up
1-year
Key result
Insulin therapy in type 2 diabetes patients post-PCI was associated with a non-significant increase in MACE compared to non-insulin therapy (12.5% vs 7.5%; adjusted HR 1.554, 95% CI 0.793-3.045).
Authors
Loading...
ITDM associated with higher post-PCI MACE; observational data leave open insulin's causal role versus confounders.
Cohort (n=465)
No
Does insulin therapy compared to non-insulin therapy increase MACE in T2DM patients following PCI?
Hazard Ratio: 1.554 (95% CI 0.793–3.045)
Absolute Event Rate: 12.5% vs 7.5%
p-value: p=0.199
Insulin-treated T2DM patients undergoing PCI may represent a higher-risk group for MACE, although the observed increase in risk was not statistically significant.
Tariq et al. (2026) conducted a cohort in Type 2 diabetes mellitus post-percutaneous coronary intervention (n=465). Insulin therapy vs. Non-insulin therapy was evaluated on MACE, a composite of non-fatal myocardial infarction (MI), stroke, coronary artery bypass grafting (CABG), repeat PCI, and mortality (HR 1.554, 95% CI 0.793-3.045, p=0.199). Insulin therapy in type 2 diabetes patients post-PCI was associated with a non-significant increase in MACE compared to non-insulin therapy (12.5% vs 7.5%; adjusted HR 1.554, 95% CI 0.793-3.045).